Year: 2023

3472696_BrandSymbol_Dakiyama_Rd

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

− Topline Results for TAK-279 Show that a Significantly Greater Proportion of Psoriatic Arthritis Patients Achieved at Least an ACR20...

1-2

Heartseed Announces the Presentation of HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure at the 71st Annual Meeting of the Japanese College of Cardiology

TOKYO--(BUSINESS WIRE)--#HS001--Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure, today announced that the case reports...

news_6

Domestic and Foreign Investment Banks, Including Citi, UBS, Nomura Orient, Industrial Securities, Huaxi Securities, and Kaiyuan Securities are Bullish on Fosun International’s Strong Profitability in Core Businesses and Sufficient Liquidity